ClinicalTrials.gg
CompletedNCT00076089Updated Dec 2, 2016

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

A Phase 3 interventional study of Roflumilast in Chronic Obstructive Pulmonary Disease and COPD, sponsored by AstraZeneca. Completed at 40 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-12-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
6th of 32
1,100 · median 154
Started
2003
with 2 others
Phase 3
16 of 32
none open now
Registered
2nd of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 3 that started in 2003, is one of 16 in phase 3, and was the 2nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • COPD

Keywords

  • Roflumilast
  • Chronic obstructive pulmonary disease
  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • /FVC ratio (post-bronchodilator) ≤70%
  • FEV1 (post-bronchodilator) ≤50% of predicted
  • Current smoker or ex-smoker
  • Clinically stable indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline
  • Availability of chest x-ray dated a maximum of 6 months prior to study baseline or a willingness to have a chest x-ray performed at baseline

Main Exclusion Criteria:

  • COPD exacerbation indicated by a treatment with systemic not stopped 4 weeks prior to baseline
  • Lower respiratory tract infection not resolved 4 weeks prior to baseline
  • Diagnosis of asthma and/or other relevant lung disease
  • Known alpha-1-antitrypsin deficiency
  • Need for long-term oxygen therapy defined as ≥16 hours/day
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. change in FEV1 from baseline during the treatment period; number of COPD exacerbations.

Secondary outcomes

  1. pulmonary function variables

  2. number of COPD exacerbations of different type and various subgroups

  3. quality of life variables

  4. patient diary variables

  5. time to study withdrawal

  6. safety.

07

Study locations

40 sites
  • ALTANA Pharma
    Cities in Alabama, Alabama, United States
  • ALTANA Pharma
    Cities in Arizona, Arizona, United States
  • ALTANA Pharma
    Cities in Arkansas, Arkansas, United States
  • ALTANA Pharma
    Cities in California, California, United States
  • ALTANA Pharma
    Cities in Colorado, Colorado, United States
  • ALTANA Pharma
    Cities in Connecticut, Connecticut, United States
  • ALTANA Pharma
    Cities in Florida, Florida, United States
  • ALTANA Pharma
    Cities in Georgia, Georgia, United States
  • ALTANA Pharma
    Cities in Illionois, Illinois, United States
  • ALTANA Pharma
    Cities in Iowa, Iowa, United States
  • ALTANA Pharma
    Cities in Kentucky, Kentucky, United States
  • ALTANA Pharma
    Cities in Louisiana, Louisiana, United States
  • ALTANA Pharma
    Cities in Massachusetts, Massachusetts, United States
  • ALTANA Pharma
    Cities in Minnesota, Minnesota, United States
  • ALTANA Pharma
    Cities in Missouri, Missouri, United States
  • ALTANA Pharma
    Cities in Montana, Montana, United States
  • ALTANA Pharma
    Cities in Nebraska, Nebraska, United States
  • ALTANA Pharma
    Cities in Nevada, Nevada, United States
  • ALTANA Pharma
    Cities in New Hampshire, New Hampshire, United States
  • ALTANA Pharma
    Cities in New Jersey, New Jersey, United States
  • ALTANA Pharma
    Cities in New York, New York, United States
  • ALTANA Pharma
    Cities in North Carolina, North Carolina, United States
  • ALTANA Pharma
    Cities in Ohio, Ohio, United States
  • ALTANA Pharma
    Cities in Oklahoma, Oklahoma, United States
  • ALTANA Pharma
    Cities in Oregon, Oregon, United States
  • ALTANA Pharma
    Cities in Pennsylvania, Pennsylvania, United States
  • ALTANA Pharma
    Cities in Rhode Island, Rhode Island, United States
  • ALTANA Pharma
    Cities in South Carolina, South Carolina, United States
  • ALTANA Pharma
    Cities in Tennessee, Tennessee, United States
  • ALTANA Pharma
    Cities in Texas, Texas, United States
  • ALTANA Pharma
    Cities in Utah, Utah, United States
  • ALTANA Pharma
    Cities in Vermont, Vermont, United States
  • ALTANA Pharma
    Cities in Virginia, Virginia, United States
  • ALTANA Pharma
    Cities in West Virginia, West Virginia, United States
  • ALTANA Pharma
    Cities in Wisconsin, Wisconsin, United States
  • ALTANA Pharma
    Cities in Canada, Canada
  • ALTANA Pharma
    Cities in France, France
  • ALTANA Pharma
    Cities in Germany, Germany
  • ALTANA Pharma
    Cities in Poland, Poland
  • ALTANA Pharma
    Cities in South Africa, South Africa
08

References and documents

Publications

  • Facius A, Krause A, Claret L, Bruno R, Lahu G. Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast. J Clin Pharmacol. 2017 Aug;57(8):1042-1052. doi: 10.1002/jcph.885. Epub 2017 Apr 17. PubMed 28419462 ↗
  • Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res. 2011 Jan 27;12(1):18. doi: 10.1186/1465-9921-12-18. PubMed 21272339 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2004
First posted
Jan 15, 2004
Start
Dec 2003
Primary completionActual
Dec 2005
CompletionActual
Dec 2005
Last update
Dec 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00076089
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 15, 2004
Start date
Dec 2003
Primary completion
Dec 2005
Completion
Dec 2005
Last update
Dec 2, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion